Research
The antibody response to human metapneumovirus
We are studying the structure and antigenic sites on the human metapneumovirus (hMPV) fusion protein. hMPV is a significant cause of lower respiratory infection in children, the elderly, and the immunocompromised. No vaccines or therapies are available for disease prevention and treatment. The fusion protein is the sole target of neutralizing antibodies. We are developing monoclonal antibody therapies for hMPV, and defining the neutralizing epitopes on the hMPV F protein to inform our vaccine design efforts.
Assessing influenza vaccine responses
Our laboratory is a member of the University of Georgia Center for Influenza Research for High Risk Populations (CIVR-HRP) focused on the development of broadly reactive influenza vaccines. We are focused on assessing the immunological and structural mechanisms by which these vaccines work, and we are studying approaches to improve their efficacy.
Broadly reactive human antibodies for Streptococcus pneumoniae
We are studying broadly reactive human antibodies for a leading cause of bacterial pneumonia, Streptococcus pneumoniae. Our lab is isolating and determining the mechanism of protection for human antibodies that protect against multiple pneumococcal serotypes. In addition, we are identifying the optimal protective epitopes targeted by these monoclonal antibodies.